371 related articles for article (PubMed ID: 23521465)
1. Evolving role of FDG PET/CT in multiple myeloma imaging and management.
Agarwal A; Chirindel A; Shah BA; Subramaniam RM
AJR Am J Roentgenol; 2013 Apr; 200(4):884-90. PubMed ID: 23521465
[TBL] [Abstract][Full Text] [Related]
2. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.
Sachpekidis C; Goldschmidt H; Dimitrakopoulou-Strauss A
Molecules; 2019 Dec; 25(1):. PubMed ID: 31905752
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma.
Peller PJ
PET Clin; 2015 Apr; 10(2):227-41. PubMed ID: 25829088
[TBL] [Abstract][Full Text] [Related]
4. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
5. Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.
Tirumani SH; Sakellis C; Jacene H; Shinagare AB; Munshi NC; Ramaiya NH; Van den Abbeele AD
Clin Nucl Med; 2016 Jan; 41(1):e7-13. PubMed ID: 26252323
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG and 18F-NaF PET/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement.
Oral A; Yazici B; Ömür Ö; Comert M; Saydam G
Clin Nucl Med; 2015 Nov; 40(11):873-6. PubMed ID: 26204214
[TBL] [Abstract][Full Text] [Related]
7. Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma?
Caldarella C; Isgrò MA; Treglia I; Treglia G
Int J Hematol; 2012 Dec; 96(6):685-91. PubMed ID: 23135876
[TBL] [Abstract][Full Text] [Related]
8. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
[TBL] [Abstract][Full Text] [Related]
9. Value of FDG PET in the assessment of patients with multiple myeloma.
Bredella MA; Steinbach L; Caputo G; Segall G; Hawkins R
AJR Am J Roentgenol; 2005 Apr; 184(4):1199-204. PubMed ID: 15788594
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT Demonstrated the Multiple Myeloma From Prostate.
Cheng A; Liping F; Wang X; Zhao L; Yang J
Clin Nucl Med; 2016 Apr; 41(4):328-30. PubMed ID: 26562573
[TBL] [Abstract][Full Text] [Related]
11. Different lesions revealed by 18F-FDG PET/CT and 18F-NaF PET/CT in patients with multiple myeloma.
Xu F; Liu F; Pastakia B
Clin Nucl Med; 2014 Sep; 39(9):e407-9. PubMed ID: 24217536
[TBL] [Abstract][Full Text] [Related]
12. Role of
Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH; San-Miguel J; Kumar SK; Richardson PG; Mikhael JR; da Costa FL; Dimopoulos MA; Zingaretti C; Abildgaard N; Goldschmidt H; Orlowski RZ; Chng WJ; Einsele H; Lonial S; Barlogie B; Anderson KC; Rajkumar SV; Durie BGM; Zamagni E
Lancet Oncol; 2017 Apr; 18(4):e206-e217. PubMed ID: 28368259
[TBL] [Abstract][Full Text] [Related]
13. 11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement.
Lapa C; Knop S; Schreder M; Rudelius M; Knott M; Jörg G; Samnick S; Herrmann K; Buck AK; Einsele H; Lückerath K
Theranostics; 2016; 6(2):254-61. PubMed ID: 26877783
[TBL] [Abstract][Full Text] [Related]
14. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
15. State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings.
Mesguich C; Fardanesh R; Tanenbaum L; Chari A; Jagannath S; Kostakoglu L
Eur J Radiol; 2014 Dec; 83(12):2203-2223. PubMed ID: 25308249
[TBL] [Abstract][Full Text] [Related]
16. Role of FDG PET in the staging of multiple myeloma.
Vicentini JRT; Bredella MA
Skeletal Radiol; 2022 Jan; 51(1):31-41. PubMed ID: 33813607
[No Abstract] [Full Text] [Related]
17. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT.
Ak İ; Onner H; Akay OM
Ann Hematol; 2015 Sep; 94(9):1567-75. PubMed ID: 26068066
[TBL] [Abstract][Full Text] [Related]
18. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
[TBL] [Abstract][Full Text] [Related]
19. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
20. Role of positron emission tomography/computed tomography in bone malignancies.
Peller PJ
Radiol Clin North Am; 2013 Sep; 51(5):845-64. PubMed ID: 24010909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
